scholarly journals Primary Hyperoxaluria Type 1 with Thrombophilia in Pregnancy: A Case Report

2018 ◽  
Vol 8 (3) ◽  
pp. 223-229
Author(s):  
Asma Hasan ◽  
Sharon Maynard ◽  
Dominick Santoriello ◽  
Henry Schairer

Background: Primary hyperoxaluria type 1 (PH1) is a rare autosomal recessive disease caused by a mutation in the AGXT gene, resulting in deficiency of the alanineglyoxylate:aminotransferase enzyme. It is characterized by accumulation of oxalate in the kidneys and other organs. Case Presentation: A Syrian woman with a history of nephrolithiasis and heterozygosity for factor V Leiden and prothrombin gene mutations presented with postpartum renal failure. She required initiation of renal replacement therapy at 14 weeks postpartum. Kidney biopsy showed severe acute and chronic crystalline deposition consistent with oxalate nephropathy. Genetic testing revealed a Gly170Arg mutation in the AGXT gene, confirming the diagnosis of PH1. Conclusions: The diagnosis of PH should be considered in patients with severe, recurrent calcium oxalate nephrolithiasis. Early treatment with pyridoxine reduces urinary oxalate excretion and can delay progression to end-stage renal disease (ESRD). After ESRD, intensive dialysis is needed to prevent systemic oxalate accumulation and deposition. Combined liver and kidney transplantation is curative. In our patient, we anticipate that liver transplantation will cure both the hyperoxaluria and the hypercoagulable state.

2015 ◽  
Vol 19 (11) ◽  
pp. 623-628 ◽  
Author(s):  
Lamiae Boualla ◽  
Mariam Tajir ◽  
Najat Oulahiane ◽  
Jaber Lyahyai ◽  
Fatima Zahra Laarabi ◽  
...  

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Hossam Murad ◽  
Mohamad Baseel Alhalabi ◽  
Amir Dabboul ◽  
Nour Alfakseh ◽  
Mohamad Sayah Nweder ◽  
...  

Abstract Background Characterization of the molecular basis of primary hyperoxaluria type 1 (PH-1) in Syria has been accomplished through the analysis of 90 unrelated chromosomes from 45 Syrians patients with PH-1 from different regions. Methods Alanine glyoxylate aminotransferase (AGXT) gene mutations have been analyzed by using molecular detection methods based on the direct DNA sequencing for all exons of the AGXT gene. Results Seventeen pathogenic mutations were detected in our patients. Six mutations were novels. The three most frequent mutations were c.33_34insC (p.Lys12fs) in Exon 1, c.584 T < G; p.Met195Arg in exon 5 and c.1007 T > A (p.Val336Asp) in exon 10, with a frequency of 33.3%, 12.2%, and 11.1%, respectively. Conclusion DNA sequencing used in this study can offer a useful method to investigate the mutations in Syrian PH-1 patients, and could offer an accurate tool for prenatal diagnosis and genetic counseling.


Nephron ◽  
2001 ◽  
Vol 87 (1) ◽  
pp. 80-84 ◽  
Author(s):  
T. David-Walek ◽  
C. Niederstadt ◽  
P.M. Rob ◽  
L. Fricke ◽  
K. Latta ◽  
...  

2015 ◽  
Vol 28 (1) ◽  
pp. 60-67
Author(s):  
Yukiko Mori ◽  
Soichi Tamamura ◽  
Kenta Yamada ◽  
Sosuke Ooto ◽  
Yasuhiro Watanabe ◽  
...  

2007 ◽  
Vol 53 (7) ◽  
pp. 1216-1221 ◽  
Author(s):  
Emma Williams ◽  
Gill Rumsby

Abstract Background: Definitive diagnosis of primary hyperoxaluria type 1 (PH1) requires analysis of alanine:glyoxylate aminotransferase (AGT) activity in the liver. We have previously shown that targeted screening for the 3 most common mutations in the AGXT gene (c.33_34insC, c.508G&gt;A, and c.731T&gt;C) can provide a molecular diagnosis in 34.5% of PH1 patients, eliminating the need for a liver biopsy. Having reviewed the distribution of all AGXT mutations, we have evaluated a diagnostic strategy that uses selected exon sequencing for the molecular diagnosis of PH1. Methods: We sequenced exons 1, 4, and 7 for 300 biopsy-confirmed PH1 patients and expressed the identified missense mutations in vitro. Results: Our identification of at least 1 mutation in 224 patients (75%) and 2 mutations in 149 patients increased the diagnostic sensitivity to 50%. We detected 29 kinds of sequence changes, 15 of which were novel. Four of these mutations were in exon 1 (c.2_3delinsAT, c.30_32delCC, c.122G&gt;A, c.126delG), 7 were in exon 4 (c.447_454delGCTGCTGT, c.449T&gt;C, c.473C&gt;T, c.481G&gt;A, c.481G&gt;T, c.497T&gt;C, c.424-2A&gt;G), and 4 were in exon 7 (c.725insT, c.737G&gt;A, c.757T&gt;C, c.776 + 1G&gt;A). The missense changes were associated with severely decreased AGT catalytic activity and negative immunoreactivity when expressed in vitro. Missense mutation c.26C&gt;A, previously described as a pathological mutation, had activity similar to that of the wild-type enzyme. Conclusions: Selective exon sequencing can allow a definitive diagnosis in 50% of PH1 patients. The test offers a rapid turnaround time (15 days) with minimal risk to the patient. Demonstration of the expression of missense changes is essential to demonstrate pathogenicity.


Sign in / Sign up

Export Citation Format

Share Document